Denali Therapeutics Inc.
NASDAQ Global SelectTotal Valuation
Denali Therapeutics Inc. carries a market capitalization of 3.54B, placing it among publicly traded companies globally. Its enterprise value stands at 3.43B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3.54B |
| Enterprise Value | 3.43B |
Share Statistics
Denali Therapeutics Inc. currently has 159.76M shares outstanding.
| Shares Outstanding | 159.76M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 1,287.84, and the price-to-book ratio stands at 4.92.
| PE Ratio | N/A |
| PS Ratio | 1,287.84 |
| PB Ratio | 4.92 |
| P/TBV Ratio | 5.14 |
| P/FCF Ratio | -10.78 |
| P/OCF Ratio | -10.69 |
Enterprise Valuation
| EV / Sales | 951.90 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Denali Therapeutics Inc. maintains a current ratio of 8.37, meaning it holds 8.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 8.37 |
| Quick Ratio | 7.93 |
| Debt / Equity | 3.86 |
| Debt / EBITDA | -0.06 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -54.93 |
| Return on Assets (ROA) | -44.01 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.04 |
Stock Price Statistics
Denali Therapeutics Inc.'s stock has gained approximately 50.64233% over the past 52 weeks. The 50-day moving average sits at 24.48, while the 200-day moving average is 20.82.
| Beta (5Y) | N/A |
| 52-Week Price Change | 50.64233% |
| 50-Day Moving Average | 24.48 |
| 200-Day Moving Average | 20.82 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Denali Therapeutics Inc. generated 3.60M in revenue and converted that into -511.45M in net income, yielding earnings per share of -2.83. EBITDA reached -526.81M, while operating income came in at -542.70M.
| Revenue | 3.60M |
| Gross Profit | 3.51M |
| Operating Income | -542.70M |
| Pretax Income | -511.35M |
| Net Income | -511.45M |
| EBITDA | -526.81M |
| EBIT | -542.70M |
| Earnings Per Share (EPS) | -2.83 |
Balance Sheet
Denali Therapeutics Inc. holds 710.47M in cash and equivalents against 32.21M in total debt, resulting in a net debt position of -201.53M. Total book value stands at 835.18M, with working capital of 663.84M providing operational flexibility.
| Cash & Cash Equivalents | 710.47M |
| Total Debt | 32.21M |
| Net Debt | -201.53M |
| Equity (Book Value) | 835.18M |
| Book Value Per Share | 5.23 |
| Working Capital | 663.84M |
Cash Flow
Denali Therapeutics Inc. produced -434.04M in operating cash flow over the past twelve months. After subtracting -3.42M in capital expenditures, free cash flow totaled -437.46M - equivalent to -2.42 per share.
| Operating Cash Flow | -434.04M |
| Capital Expenditures | -3.42M |
| Free Cash Flow | -437.46M |
| FCF Per Share | -2.42 |
Margins
Denali Therapeutics Inc. operates with a gross margin of 97.42, reflecting its pricing power and cost economics. The operating margin of -15,058.19 and net profit margin of -14,191.20 provide insight into operational efficiency.
| Gross Margin | 97.42 |
| Operating Margin | -15,058.19 |
| Pretax Margin | -14,188.37 |
| Profit Margin | -14,191.20 |
| EBITDA Margin | -14,617.31 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -10.35 |
| FCF Yield | -9.28 |
Scores
Denali Therapeutics Inc. posts an Altman Z-Score of 3.88, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.88 |